Taken together, Rho-kinase inhibition might be an additive strategy to improve survival in renovascular hypertension with reduced renal mass, whereas low-dose AT1 blockade might be a therapeutic choice in all other cases of renovascular hypertension. This evidence concerns the gene AGTR1 and renovascular hypertension.